82P Stock Chart & Stats
€22.00
€0.00(0.00%)
At close: 4:00 PM EDT
€22.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€15.40 - €23.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€876.02M
Enterprise Value€1.18K
Total Cash (Recent Filing)€251.03M
Total Debt (Recent Filing)€412.12M
Price to Earnings (P/E)70.1
Beta0.54
Next Earnings
Oct 29, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding39,861,885
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.51
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.64Price Target Upside12.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)2.48
Revenue Forecast (FY)€646.89M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong operating and free cash flow indicate that Pacira converts reported earnings into usable cash, supporting investment, debt reduction, and resilience. This internally generated liquidity provides flexibility as the company funds development programs and manages year-to-year earnings volatility.
Expanded Payer AccessBroader reimbursement coverage can reduce access barriers and support durable adoption of EXPAREL and ZILRETTA across healthcare providers. Preferred formulary placement and expanding covered lives strengthen commercial reach, potentially improving utilization as procedures migrate to outpatient settings.
Pipeline And Manufacturing ProgressAdvancing PCRX-201 through clinical development while establishing scalable domestic manufacturing improves the potential for a repeatable future product platform. The combination of clinical validation and production readiness can support commercialization and diversify growth beyond current products.
Bears Say
Gross Margin CompressionThe four-point margin decline shows that Pacira’s strong gross-profit profile is not fully insulated from product mix, inventory, or operating changes. Persistent compression would reduce cash available for research and commercialization, making sustained earnings improvement more difficult.
Procedure Demand And EXPAREL ModerationPacira remains exposed to procedure volumes and reimbursement structures, particularly where EXPAREL is not separately reimbursed outside bundled inpatient payments. Softer elective demand and moderating product growth could constrain near-term revenue expansion despite outpatient migration.
NOPAIN Policy UncertaintyUncertainty around future CMS reimbursement creates a structural adoption risk for Pacira’s non-opioid pain strategy. If renewal or rulemaking outcomes are unfavorable, hospitals and providers could face weaker economic incentives to use EXPAREL, limiting utilization and revenue visibility.
Pacira Pharmaceuticals News
82P FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was €15.40 and its highest was €23.80 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is €876.02M.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 44 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Aug 04, 2026. The company reported €0.628 earnings per share for the quarter, beating the consensus estimate of €0.555 by €0.072.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.62.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 39,861,885 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of €0.628 in its last earnings report, beating expectations of €0.555. Following the earnings report the stock price went down -3.419%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:82P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€24.64 (12.02% Upside)
€24.64 (12.02% Upside)
Blogger Sentiment
Bullish
DE:82P Sentiment 67%
Sector Average 62%
Sector Average 62%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pacira Pharmaceuticals
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
82P Company Deck
82P Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted solid financial performance (6% revenue growth, robust adjusted EBITDA, strong cash position), meaningful commercial progress (major payer wins covering ~150M lives, EXPAREL and ZILRETTA momentum), important pipeline and manufacturing milestones (PCRX-201 manufacturing, multiple imminent readouts), and a strategic portfolio move (iovera divestiture with up to $140M consideration). Key challenges include softness in elective inpatient soft tissue procedures driven by macroeconomic factors, a decline in gross margin versus prior year, higher R&D and SG&A spend, and modest near-term moderation in EXPAREL volume growth. Overall, the positives — including clear payer wins, pipeline catalysts, cash generation, and strategic partnerships — outweigh the operational and margin headwinds.View all DE:82P earnings summaries82P Stock 12 Month Forecast
Average Price Target
€24.64
▲(12.02% Upside)
Technical Analysis
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―